The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications


      To determine the impact of physicians' financial relationships with the pharmaceutical industry on prescribing marketed alpha-blockers and overactive bladder (OAB) medications. We also aim to examine if the number or total value of transactions is influential.

      Materials and Methods

      We linked the Open Payments Program database of industry payments to prescribers with Medicare Part D prescription data. We used binomial logistic regression to identify the association between receipt of industry payment and prescribing of marketed alpha-blockers (silodosin) and OAB medications (fesoterodine, solifenacin, and mirabegron). We also evaluated the impact of increasing total value and number of payments on prescribing of marketed drugs.


      The receipt of industry payment was associated with increased odds of prescribing the marketed drug for all included drugs: silodosin (odds ratio [OR] 34.1), fesoterodine (OR 5.9), solifenacin (OR 2.7), and mirabegron (OR 6.8) (all P <.001). We also found that increasing value of total payment and increasing frequency of payments were both independently associated with increased odds of prescribing with a dose-response effect.


      There is a consistent association between receipt of industry payment and prescribing marketed alpha-blockers and OAB medications. Both the total value and number of transactions were associated with prescribing.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Campbell E.G.
        • Gruen R.L.
        • Mountford J.
        • et al.
        A national survey of physician-industry relationships.
        N Engl J Med. 1742; 356: 2007
        • Santhakumar S.
        • Adashi E.Y.
        The physician payment sunshine act: testing the value of transparency.
        JAMA. 2015; 313: 23
        • Tringale K.R.
        • Marshall D.
        • Mackey T.K.
        • et al.
        Types and distribution of payments from industry to physicians in 2015.
        JAMA. 2017; 317: 1774
      1. Open Payments—Centers for Medicare & Medicaid Services.
        (Available at)
        Date accessed: November 6, 2017
        • Perlis R.H.
        • Perlis C.S.
        Physician payments from industry are associated with greater Medicare Part D prescribing costs.
        PLoS ONE. 2016; 11 (e0155474)
        • Fleischman W.
        • Agrawal S.
        • King M.
        • et al.
        Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.
        BMJ. 2016; 354: i4189
        • Taylor S.C.
        • Huecker J.B.
        • Gordon M.O.
        • et al.
        Physician-industry interactions and anti-vascular endothelial growth factor use among US ophthalmologists.
        JAMA Ophthalmol. 2016; 134: 897
        • Bandari J.
        • Ayyash O.M.
        • Turner 2nd, R.M.
        • et al.
        The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
        Cancer. 2017; 123: 4356
        • Bandari J.
        • Turner 2nd, R.M.
        • Jacobs B.L.
        • et al.
        The relationship of industry payments to prescribing behavior: a study of degarelix and denosumab.
        Urol Pract. 2017; 4: 14
        • Kirk P.S.
        • Borza T.
        • Dupree J.M.
        • et al.
        Potential savings in Medicare part D for common urological conditions.
        Urol Pract. 2017;
        • Dahm P.
        • Brasure M.
        • MacDonald R.
        • et al.
        Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta-analysis.
        Eur Urol. 2017; 71: 570
        • Sah S.
        • Fugh-Berman A.
        Physicians under the influence: social psychology and industry marketing strategies.
        J Law Med Ethics. 2013; 41: 665
        • Oldani M.J.
        Thick prescriptions: toward an interpretation of pharmaceutical sales practices.
        Med Anthropol Q. 2004; 18: 325
        • Yeh J.S.
        • Franklin J.M.
        • Avorn J.
        • et al.
        Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts.
        JAMA Intern Med. 2016; 176: 763
        • DeJong C.
        • Aguilar T.
        • Tseng C.W.
        • et al.
        Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries.
        JAMA Intern Med. 2016; 176: 1114
        • Pellegrino E.D.
        Professionalism, profession and the virtues of the good physician.
        Mt Sinai J Med. 2002; 69: 378